Intestinal Microbiome Changes and Clinical Outcomes of Patients with Ulcerative Colitis after Fecal Microbiota Transplantation
-
Published:2023-12-15
Issue:24
Volume:12
Page:7702
-
ISSN:2077-0383
-
Container-title:Journal of Clinical Medicine
-
language:en
-
Short-container-title:JCM
Author:
Tikunov Artem Y.1ORCID, Fedorets Valeria A.1, Shrainer Evgenia V.12ORCID, Morozov Vitaliy V.1, Bystrova Valeria I.12ORCID, Tikunova Nina V.1
Affiliation:
1. Federal State Public Scientific Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia 2. Department of Obstetrics and Gynecology, V. Zelman Institute for Medicine and Psychology, Novosibirsk National Research State University, 630090 Novosibirsk, Russia
Abstract
Background and Aims: Ulcerative colitis (UC) is a chronic inflammatory disease that affects many people. One of the possible ways to treat UC is fecal microbiota transplantation (FMT). In this study, changes in the intestinal microbiome and clinical outcomes of 20 patients with UC after FMT were estimated. Methods: FMT enemas were administrated ten times, once a day, and fecal microbiota from three donors was used for each enema. The clinical outcomes were assessed after eight weeks and then via a patient survey. The 16S rRNA profiles of the gut microbiota were compared between three samplings: samples from 20 patients with UC before and after FMT and samples from 18 healthy volunteers. Results: Clinical remission was achieved in 19 (95%) patients at week 8. Adverse events occurred in five patients, including one non-responder. A significant increase in average biodiversity was shown in samples after FMT compared to samples before FMT, as well as a decrease in the proportion of some potentially pathogenic bacteria. Conclusion: The efficacy of FMT for UC treatment was confirmed; however, the duration of remission varied substantially, possibly due to different characteristics of the initial microbiota of patients. Targeted analysis of a patient’s microbiome before FMT could increase the treatment efficacy.
Funder
Russian Science Foundation
Reference77 articles.
1. The Human Gut Microbiome: From Association to Modulation;Schmidt;Cell,2018 2. Human Gut Microbiota/Microbiome in Health and Diseases: A Review;Gomaa;Antonie Van Leeuwenhoek,2020 3. King, C.H., Desai, H., Sylvetsky, A.C., LoTempio, J., Ayanyan, S., Carrie, J., Crandall, K.A., Fochtman, B.C., Gasparyan, L., and Gulzar, N. (2019). Baseline Human Gut Microbiota Profile in Healthy People and Standard Reporting Template. PLoS ONE, 14. 4. Rinninella, E., Cintoni, M., Raoul, P., Lopetuso, L.R., Scaldaferri, F., Pulcini, G., Miggiano, G.A.D., Gasbarrini, A., and Mele, M.C. (2019). Food Components and Dietary Habits: Keys for a Healthy Gut Microbiota Composition. Nutrients, 11. 5. Afzaal, M., Saeed, F., Shah, Y.A., Hussain, M., Rabail, R., Socol, C.T., Hassoun, A., Pateiro, M., Lorenzo, J.M., and Rusu, A.V. (2022). Human Gut Microbiota in Health and Disease: Unveiling the Relationship. Front. Microbiol., 13.
|
|